Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
- PMID: 24714323
- PMCID: PMC3959484
Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Abstract
Aim: To investigate the effect of surgery on overall survival (measured from the time of diagnosis) in pancreatic cancer without vascular invasion (stage 1, 2A and 2B). We also sought to investigate factors that predict survival in patients who elected to undergo surgery and factors that affect the decision to undergo surgery.
Methods: The Surveillance Epidemiology and End Results (SEER) database was queried for microscopically confirmed cases of stage 1,2A and 2B pancreatic ductal adenocarcinoma diagnosed between 1973-2009. Survival analysis was carried out by univariate and multivariate analysis. Logistic regression was employed to identify factors that predict decision to undergo surgery.
Results: 1,759 patients with microscopically confirmed pancreatic cancer with stage 1-2B at the time of diagnosis were recorded in the SEER database. 92.6% patients underwent pancreatic cancer-directed surgery. Patients undergoing surgery had a significantly lower mean age at the time of diagnosis (65.8 vs. 69.9 years, P=0.002) and a longer median survival (18 vs. 7 months) compared to those who did not undergo surgery. Surgical resection was a significant predictor of overall survival upon both univariate and multivariate analysis. Younger age at the time of diagnosis, non-white, non-black race, tumor size <40 mm and tumor located in the tail of the pancreas were factors significantly associated with a chance of pancreatic cancer-directed surgery.
Conclusion: Surgery improves survival in pancreatic cancer patients where the tumor has not involved the vasculature. Younger patients, those with smaller tumors located in the tail of the pancreas were most likely to undergo surgical resection.
Keywords: Pancreatic cancer; survival; vascular invasion.
Conflict of interest statement
Conflict of Interest: None
Figures

Similar articles
-
Underuse of surgical resection among elderly patients with early-stage pancreatic cancer.Surgery. 2015 Nov;158(5):1226-34. doi: 10.1016/j.surg.2015.04.031. Epub 2015 Jun 29. Surgery. 2015. PMID: 26138347
-
Early-onset pancreatic cancer: a population-based study using the SEER registry.Langenbecks Arch Surg. 2019 Aug;404(5):565-571. doi: 10.1007/s00423-019-01810-0. Epub 2019 Aug 3. Langenbecks Arch Surg. 2019. PMID: 31377855 Free PMC article.
-
672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma.Surgery. 2008 Aug;144(2):141-8. doi: 10.1016/j.surg.2008.03.006. Epub 2008 May 27. Surgery. 2008. PMID: 18656619
-
Primary sarcomas of the pancreas: A review of 253 patients from the National Cancer Data Base.Surg Oncol. 2018 Dec;27(4):676-680. doi: 10.1016/j.suronc.2018.08.006. Epub 2018 Sep 7. Surg Oncol. 2018. PMID: 30449492 Review.
-
[Prospects for standardization of surgical procedures for carcinoma of the pancreas].Nihon Geka Gakkai Zasshi. 2003 May;104(5):412-21. Nihon Geka Gakkai Zasshi. 2003. PMID: 12774526 Review. Japanese.
Cited by
-
Can computational modeling help in personalizing the care of patients with pancreatic ductal adenocarcinoma?Ann Pancreat Cancer. 2018 May;1(5):17. doi: 10.21037/apc.2018.05.01. Epub 2018 May 24. Ann Pancreat Cancer. 2018. PMID: 32601615 Free PMC article. No abstract available.
-
Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.BMC Cancer. 2021 Jan 11;21(1):49. doi: 10.1186/s12885-020-07736-x. BMC Cancer. 2021. PMID: 33430810 Free PMC article. Clinical Trial.
-
Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.BMC Cancer. 2022 Feb 16;22(1):174. doi: 10.1186/s12885-022-09255-3. BMC Cancer. 2022. PMID: 35172762 Free PMC article.
-
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.J Manag Care Spec Pharm. 2021 Oct;27(10):1367-1375. doi: 10.18553/jmcp.2021.27.10.1367. J Manag Care Spec Pharm. 2021. PMID: 34595948 Free PMC article. Clinical Trial.
-
Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.Abdom Radiol (NY). 2021 Oct;46(10):4765-4778. doi: 10.1007/s00261-021-03127-3. Epub 2021 Jun 3. Abdom Radiol (NY). 2021. PMID: 34085090
References
-
- Chakraborty S, Hauke RJ, Bonthu N, Tarantolo SR. Increased incidence of a second lymphoproliferative malignancy in patients with multiple myeloma - a SEER based study. Anticancer Res. 2012;32:4507–4515. - PubMed
-
- Vargas R, Nino-Murcia M, Trueblood W, Jeffrey RB., Jr MDCT in Pancreatic adenocarcinoma: prediction of vascular invasion and resectability using a multiphasic technique with curved planar reformations. Am J Roentgenol. 2004;182:419–425. - PubMed
-
- Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg. 2006;10:1199–1210. - PubMed
-
- Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586–594. - PubMed
Publication types
LinkOut - more resources
Full Text Sources